Verified Panel · Trauma-Informed · One-on-One
Depth that a group or survey
cannot deliver
Some research questions in rare disease cannot be answered in a group setting, and some cannot be answered with a survey instrument at all. When you need to understand a single patient’s diagnostic odyssey in full, probe a KOL’s clinical reasoning in depth, or explore a sensitive topic a group format would inhibit, the in-depth interview is the right tool.
MedPanel conducts one-on-one IDIs with verified rare disease patients, caregivers, and physicians across a global panel, applying the same verification and IRB-ready rigor that defines our broader research practice — calibrated to the depth that only individual interviews can deliver.
Journeys · Sensitive topics · Ultra-rare · KOLs
Patient/caregiver 45–60 min · KOL 60–90 min
Virtual by default, secure platform
Attestation · Medical record · Screening
When an IDI Is the Right Methodology
IDIs are not simply a smaller version of a focus group. They serve four distinct research objectives that group formats and surveys cannot satisfy.
- Individual diagnostic journeys. Rare disease patients frequently experience years-long diagnostic odysseys involving multiple misdiagnoses, specialist referrals, and periods of uncertainty. Capturing this journey with the narrative detail needed for patient journey mapping, awareness campaign development, or health economic modeling requires uninterrupted, individually paced interview time — something a focus group format actively works against, since group dynamics compress and homogenize individual narratives.
- Sensitive or stigmatized topics. Conditions involving visible physical differences, fertility implications, end-of-life considerations, or mental health comorbidities often surface more candidly one-on-one than in a group, where participants may self-censor in front of peers — even peers who share their diagnosis. MedPanel’s moderators are trained in trauma-informed interview techniques specific to these contexts.
- Ultra-rare populations where group assembly is not feasible. For conditions with global patient counts in the low hundreds, even a 2–4 person group may be logistically unachievable within a reasonable fielding timeline. IDIs allow research to proceed at whatever pace the population permits, without compromising study design by combining incompatible participants simply to fill a group.
- Key opinion leader interviews. Distinct from patient and caregiver IDIs, KOL interviews probe clinical reasoning, unpublished treatment experience, and forward-looking perspective on emerging therapies — content that requires expert-to-expert dialogue depth rather than structured survey questions.
IDI Methodology and Interview Design
MedPanel’s IDI protocols are built around semi-structured discussion guides — sufficient structure to ensure comparability across interviews, sufficient flexibility to follow unexpected threads that a rigid instrument would foreclose.
Interview length
Length varies by respondent type and topic depth. Patient and caregiver IDIs in rare disease typically run 45–60 minutes; KOL interviews often extend to 60–90 minutes given the clinical ground to cover. MedPanel calibrates length to respondent burden as carefully as to research objectives — a 90-minute interview is inappropriate for a patient managing significant fatigue or cognitive burden from their condition, regardless of how much ground the discussion guide could theoretically cover.
Virtual delivery
Interviews are conducted virtually by default, using the same secure platform infrastructure as MedPanel’s focus group offering, with the same minimal technical requirements for participants. This is particularly valuable for rare disease IDI recruitment, where the right respondent for a highly specific research question may be located anywhere in the world.
Moderator continuity
Moderator continuity matters more in IDI work than in any other qualitative format. Because each interview stands largely on its own — there is no group dynamic to surface comparative reactions — moderator skill in probing, follow-up sequencing, and rapport-building directly determines data quality. MedPanel assigns moderators with relevant therapeutic area familiarity wherever possible, particularly for KOL interviews where credibility with the respondent affects candor.
Analysis Approach for IDI Data in Rare Disease
IDI data is analytically rich but structurally different from survey data — rare disease teams should plan their analysis approach before fielding begins, not after.
Thematic analysis across a small number of interviews requires a different rigor standard than thematic analysis across a large qualitative sample. With ultra-rare populations yielding perhaps 8–15 total interviews, each individual narrative carries proportionally greater analytical weight, and MedPanel’s analysts apply structured coding frameworks designed specifically for small-N qualitative synthesis — distinguishing genuinely shared themes from single-respondent idiosyncrasy.
Cross-respondent triangulation becomes particularly valuable when IDIs are fielded alongside other methodologies. Patient IDI findings checked against physician IDI findings on the same clinical questions — diagnostic delay causes, treatment switching triggers, unmet need prioritization — frequently surface discrepancies that are themselves the most valuable finding in the study, revealing gaps between clinical assumption and lived patient experience.
Verified Panel Access for IDI Recruitment
Because an IDI is a significant time investment from both respondent and budget, recruitment errors are costlier here than in larger-N studies.
IDI recruitment in rare disease faces the same verification challenge as every other methodology MedPanel offers: confirming that a single, specific individual genuinely has the diagnosis, caregiving relationship, or clinical role required for the study. Because an IDI represents a significant time investment from both the respondent and the research budget, recruitment errors are costlier here than in larger-N studies.
MedPanel’s verified panel — built on physician attestation, medical record confirmation, and condition-specific screening rather than self-report — extends to IDI recruitment with the same standard applied across our focus group, survey, and caregiver study offerings. Combined with global reach across North America, Europe, Asia-Pacific, and Latin America, this allows MedPanel to locate and verify the specific individual respondents that highly targeted rare disease IDI studies require.
Plan your IDIs
Plan Your Rare Disease IDI Program
When your research question demands depth that a group or survey format cannot deliver, an in-depth interview program built on a verified panel is the right investment. MedPanel will help you determine whether IDIs, focus groups, or a combined approach best fit your study objectives.
One-on-one depth for journeys, sensitive topics & KOLs
Trauma-informed moderators with therapeutic-area familiarity
Small-N analysis frameworks built for ultra-rare samples
Verified recruitment of specific, high-value respondents
Contact MedPanel to discuss your in-depth interview program for rare disease patients, caregivers, or physicians. We will confirm feasibility and outline an interview design suited to your research questions.